CTLA4 and cancer: The classical checkpoint blockade hypothesis stipulates that anti-CTLA-4 mAbs promote cancer immunity by blocking a negative signal of the B7-CTLA-4 interaction to promote naïve T cell activation in the lymphoid organ.15 According to this model, therapeutic antibodies are antagonists that functionally inactivate CTLA-4:B7 interactions.